Health ❯ Medicine ❯ Pharmaceuticals ❯ Oncology

Multiple Myeloma

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Regulators limited the relaunch to one regimen because safety concerns offset strong efficacy data.

Bristol Myers’ Iberdomide Combo Hits MRD Goal in Phase 3 Myeloma Study